Mouse model of subretinal neovascularization with choroidal anastomosis

被引:126
作者
Heckenlively, JR
Hawes, NL
Friedlander, M
Nusinowitz, S
Hurd, R
Davisson, M
Chang, B
机构
[1] Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA
[2] Jackson Lab, Bar Harbor, ME 04609 USA
[3] Scripps Res Inst, Dept Cell Biol, La Jolla, CA USA
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2003年 / 23卷 / 04期
关键词
D O I
10.1097/00006982-200308000-00012
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To characterize the phenotype and report a reliable genetic model of retinal angiogenesis and subretinal neovascularization in the mouse. Methods: The mouse phenotype was characterized using ophthalmoscopy, fundus photography, fluorescein angiography, electroretinography, histology, gene sequencing, and linkage analysis. Results: Scattered pink-gray retinal lesions were found on ophthalmoscopy and were confirmed to be subretinal neovascularization on fluorescein angiography. On histologic examination, outer plexiform retinal neovascularization with growth into the subretinal space was found as early as postnatal Day 15. On genetic analysis, homozygosity of the Vldlr mutation always segregated with the retinal angiogenesis, whereas normal and heterozygous mice had no neovascularization. The histologic studies 15 to 18 days consistently showed new outer plexiform neovascular vessels drawn to the subretinal space by 20 days, and by 30 to 50 days, subretinal hemorrhages and choroidal anastomoses were common. Mice by 8 months had increased vascularity of the iris and ciliary body. Conclusions: The Vldlr mutation in the mouse provides a good model for retinal angiogenesis and subretinal neovascularization. Finding a strong association between retinal angiogenesis and a very low density lipid receptor mutation is new, and study of lipid receptor physiology may broaden the understanding of retinal angiogenesis.
引用
收藏
页码:518 / 522
页数:5
相关论文
共 25 条
[1]  
Ambati BK, 2002, ARCH OPHTHALMOL-CHIC, V120, P1063
[2]  
DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
[3]  
FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
[4]  
Green W R, 1999, Mol Vis, V5, P27
[5]  
Hawes N L, 1999, Mol Vis, V5, P22
[6]  
HAYREH SS, 1983, OPHTHALMOLOGY, V90, P488
[7]   Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor [J].
Hembrough, TA ;
Ruiz, JF ;
Papathanassiu, AE ;
Green, SJ ;
Strickland, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (15) :12241-12248
[8]   Inhibitory effect of bucillamine on laser-induced choroidal neovascularization in rats [J].
Hikichi, T ;
Mori, F ;
Sasaki, M ;
Takamiya, A ;
Nakamura, M ;
Shishido, N ;
Takeda, M ;
Horikawa, Y ;
Matsuoka, H ;
Yoshida, A .
CURRENT EYE RESEARCH, 2002, 24 (01) :1-5
[9]   Fas ligand (CD95 ligand) controls angiogenesis beneath the retina [J].
Kaplan, HJ ;
Leibole, MA ;
Tezel, T ;
Ferguson, TA .
NATURE MEDICINE, 1999, 5 (03) :292-297
[10]  
KESLWARA L, 2002, J NEUROSCI, V22, P4869